medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2022, Number 04

<< Back Next >>

Ginecol Obstet Mex 2022; 90 (04)

Myasthenia gravis as a paraneoplastic syndrome in a ovarian tumor. Case report and review of the literature

Guilombo-Salcedo G, Barrera-Neira CA, Gutiérrez-Álvarez C

Language: Spanish
References: 17
Page: 371-377
PDF size: 246.03 Kb.


ABSTRACT

Background: Paraneoplastic syndromes are distant manifestations of neoplasms originated by secondary mechanisms but not by tumor invasion. They are infrequent, precede the manifestation of the tumor itself and disappear when the tumor is cured. Although myasthenia gravis has traditionally been related to thymomas, here we report a case of myasthenia gravis as a paraneoplastic syndrome of an ovarian tumor and review the available literature on its diagnosis.
Clinical case: 46-year-old patient with multiple episodes of generalized weakness and ventilatory failure requiring mechanical ventilation and intensive care stay. The clinical diagnosis of myasthenia gravis was established. Despite adequate treatment and thymectomy, the crises persisted. Soon after, she was diagnosed with serous adenocarcinoma of the ovary, which was treated with surgery and chemotherapy. With this, the neurological symptoms disappeared, with total remission after four years of follow-up, without medical treatment. For the literature review a search was undertaken in Medline, Cochrane, LILACS, Google Scholar and grey literature with the terms "myasthenia gravis AND ovarian cancer". Eighteen articles were found of which only two publications were included for the full review.
Conclusions: Neurological syndromes, among this myasthenia gravis, associated with ovarian tumors as paraneoplastic syndromes are rare and raise the need to include gynecological study in patients with myasthenia gravis of atypical manifestation.


REFERENCES

  1. Li W-H, Cao D-Y, Shen K, Yang J-X. A Rare Case of Ovarian Cancer Presenting with Paraneoplastic Cerebellar Degeneration and Limbic Encephalitis. Chin Med J (Engl) 2015; 128 (19): 2685-7. doi: 10.4103/0366-6999.166028

  2. Rosenfeld MR, Dalmau J. Paraneoplastic Neurologic Syndromes. Neurol Clin 2018; 36 (3): 675-85. doi: 10.1016/j. ncl.2018.04.015

  3. Marx A, Willcox N, Leite MI, Chuang W-Y, Schalke B, Nix W, et al. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity 2010; 43 (5-6):413–27. doi: 10.3109/08916930903555935

  4. Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol 2016; 263 (8): 1473-94. doi: 10.1007/s00415-016-8045-z

  5. Strobel P, Preisshofen T, Helmreich M, Muller-Hermelink HK, Marx A. Pathomechanisms of paraneoplastic myasthenia gravis. Clin Dev Immunol 2003; 10 (1): 7-12. doi: 10.1080/10446670310001598528

  6. Binks S, Vincent A, Palace J. Myasthenia gravis: a clinicalimmunological update. J Neurol 2016; 263 (4): 826-34. doi: 10.1007/s00415-015-7963-5

  7. Ciafaloni E. Myasthenia Gravis and Congenital Myasthenic Syndromes. Continuum (Minneap Minn) 2019; 25 (6): 1767-84. doi: 10.1212/CON.0000000000000800

  8. Gwathmey KG, Burns TM. Myasthenia Gravis. Semin Neurol 2015; 35 (4): 327-39. doi: 10.1055/s-0035-1558975

  9. Hehir MK, Silvestri NJ. Generalized Myasthenia Gravis: classification, clinical presentation, natural history, and epidemiology. Neurol Clin 2018; 36 (2): 253-60. doi: 10.1016/j.ncl.2018.01.002

  10. Vazquez-Pelillo J, Gil Alonso J, Diaz-Agero P, Garcia Sanchez- Giron J, Roca Serrano R, Diez Tejedor E, et al. Análisis de factores pronósticos y resultados de la timectomía en 80 casos de miastenia gravias. Arch Bronconeumol 2001; 37 (4): 16670. doi: 10.1016/S0300-2896(01)75045-4

  11. Henry K. Paraneoplastic syndromes: Definitions, classification, pathophysiology and principles of treatment. Semin Diagn Pathol 2019; 36 (4): 204-10. doi: 10.1053/j. semdp.2019.01.002

  12. Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol 2010; 67 (3): 330-5. doi: 10.1001/ archneurol.2009.341

  13. Zaborowski MP, Spaczynski M, Nowak-Markwitz E, Michalak S. Paraneoplastic neurological syndromes associated with ovarian tumors. J Cancer Res Clin Oncol 2015; 141 (1): 99-108. doi: 10.1007/s00432-014-1745-9

  14. Negishi Y, Sakai K, Noguchi Y, Iwasaki N, Kawai N. Paraneoplastic cerebellar degeneration caused by ovarian clear-cell carcinoma. J Obstet Gynaecol Res 2014; 40 (2): 614-7. doi: 10.1111/jog.12212

  15. Chien H-J, Lee C-Y, Chen L-A, Wu C-C, Chang C-L. Paraneoplastic cerebellar degeneration in a patient with ovarian cancer. Taiwan J Obstet Gynecol 2015; 54 (3): 313-5. doi: 10.1016/j.tjog.2014.03.012

  16. Caliandro P, Luigetti M, Ricci E, Mirabella M, Tonali PA, Padua L. Cerebellar degeneration and ocular myasthenia gravis in a patient with recurring ovarian carcinoma. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 2010; 31 (1): 79-81. doi: 10.1007/s10072-009-0154-3

  17. Simonsen M, Miyabe MM, Ouki HT, Galvao ACR, Leite D, Murayama BAR, et al. Myasthenia as a paraneoplastic manifestation of ovarian cancer. Gynecologic oncology reports. Netherlands 2018; 25: 35-6. doi: 10.1016/j. gore.2018.05.008




2020     |     www.medigraphic.com